Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis. Issue 2 (3rd May 2022)

• Record Type: Journal Article
• Authors: Karampitsakos, Theodoros; Papaioannou, Ourania; Dimeas, Ilias; Tsiri, Panagiota; Sotiropoulou, Vasilina; Tomos, Ioannis; Papanikolaou, Ilias C.; Katsaras, Matthaios; Kirgou, Paraskevi; Daniil, Zoe; Gourgoulianis, Konstantinos I.; Sampsonas, Fotios; Manali, Effrosyni; Papiris, Spyridon; Bouros, Demosthenes; Tzouvelekis, Argyris
• Is Part Of: ERJ open research. Volume 8:Issue 2(2022)
• Publication Date: 2022-05-03
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00082-2022
• Languages: English
• ISSNs: 2312-0541

Abstract

The emergence and spread of 2019 coronavirus disease (COVID-19) are causing a growing global public health crisis. Despite advances in treatment, vaccination remains the best way to contain the pandemic [1]. Vaccines are available by means of conditional marketing approval, full approval and emergency use authorisation pathways [2]. Evidence suggest that immunocompromised individuals, including solid-organ transplant recipients and patients under immunosuppressive treatment, may have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite double-dose mRNA vaccine regimens [3]. This is partially attributed to blunted immune responses to vaccination, since only 38–54% of kidney and liver transplant recipients developed detectable SARS-CoV-2 antibodies following the second dose of mRNA vaccines [3, 4]. Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0